Literature DB >> 8129383

[Neoadjuvant chemotherapy for far-advanced gastric carcinoma].

M Mai1, Y Takahashi, T Fujimoto, K Omote.   

Abstract

Far-advanced gastric carcinoma of the stomach remains a lethal disease, showing a particularly poor prognosis in the patients with linitis plastica type. Considering the high potential for biological malignancies, we attempted preoperative induction (neoadjuvant) chemotherapy against far-advanced cancer associated with distant metastases. Anticancer drugs used in this study were FAM or sequential MTX/5-FU. Neoadjuvant chemotherapy was carried out on 24 patients prior to surgery. The response to chemotherapy showed shrinking of massive nodal involvement in 50% (5/10) and complete disappearance of malignant ascites in 87.5% (7/8). The morphological improvement of primary gastric lesions was obtained in 9 out of 24 cases (37.5%). In 15 cases (68.2%) total gastrectomy was done with extended lymph node dissection. In one of 9 cases showing marked improvement, no viable cancer cells were seen in whole stomach associated with multiple foci of granulomatous lesions of regional nodes after 3 cycles of MTX/5-FU. Disease-free survival of neoadjuvant group showed a significant prolongation of its median survival of 14 months, compared to that of 4-6 months in the surgery alone group. Our result leads to the conclusion that the patients whose tumor was effectively destroyed by neoadjuvant chemotherapy had a good prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129383

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

Review 1.  Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy.

Authors:  Umme Hani; Riyaz Ali M Osmani; Sabina Yasmin; B H Jaswanth Gowda; Hissana Ather; Mohammad Yousuf Ansari; Ayesha Siddiqua; Mohammed Ghazwani; Adel Al Fatease; Ali H Alamri; Mohamed Rahamathulla; M Yasmin Begum; Shadma Wahab
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

Review 2.  Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.

Authors:  Xian-Ze Wang; Zi-Yang Zeng; Xin Ye; Juan Sun; Zi-Mu Zhang; Wei-Ming Kang
Journal:  World J Gastrointest Oncol       Date:  2020-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.